Summary Of Clinical Experience And Experimental Study On The Treatment Of Diffuse Interstitial Lung Disease With The Method Of Replenishing Qi And Activating Blood Circulatio

Objective:To investigate the theoretical basis and clinical experience of the Beneficial Qi and Blood method in the treatment of diffuse parenchymal lung disease;to investigate the therapeutic effect and mechanism of action of the Beneficial Qi and Blood method on pulmonary fibrosis based on the intervention of Pulmonary Fibrosis Capsules in a mouse model of pulmonary fibrosis.Method:1.Clinical aspects:Based on theoretical research and Professor Wang Yuguang’s clinical application of the Beneficial Qi and Invigorating Blood method in the treatment of diffuse parenchymal lung disease.2.Experimental aspects:60 C57BL/6J male mouse were divided into 5 groups,namely control group,model group,pirfenidone group,high-dose group of Bufei Huoxue Capsule and low-dose group of Bufei Huoxue Capsule,12 mouse in each group.Except for the control group,the mouse model of pulmonary fibrosis was established by tracheal drip injection of bleomycin in all other groups.The treatment was started on the first day after modeling.The low-dose and high-dose groups were given 315 mg/kg/d and 630 mg/kg/d of Bufei Huoxue Capsule by gavage,respectively,and the pirfenidone group was given 200 mg/kg/d by gavage.The lung tissues of mouse were collected after 28 days of continuous administration,and the histopathological changes were observed by HE and Masson methods,respectively.The expression levels of p-PI3K and p-Akt proteins were detected by immunohistochemistry.Result:1.General conditions:Compared with the control group,the mouse in the model group are significantly reduced,and the general conditions such as activity,fur color,and diet are significantly low.Compared with the model group,the mouse in the high dose group of the Bufei Huoxue Capsule,PFD group are high in weight,and general conditions such as activity,fur color,and diet are high.2.Observation of pulmonist tissue pathology:Compared with the control group,the display structure of the mouse lung tissue pathology in the model group is obviously destroyed,inflammatory cell exudation and collagen fiber deposition;Compared with the modole group,the lung tissue structure of high dose group of the Bufei Huoxue Capsule and PFD group improved significantly,inflammatory cell exudation,and collagen fiber deposition significantly decreased significantly.3.HYP content:Compared with the control group,the HYP content in the mouse lung tissue in the model group is significantly increased(P<0.01);compared with the model group,the high dose group of the Bufei Huoxue Capsule,the PFD group mouse’s HYP content in the lung tissue is significantly reduced(P<0.01).The HYP content of mice in the high dose group of the Bufei Huoxue Capsule and the pirfenidone group was close,and the difference was not statistically significant.4.Relatively expression volume of COL-Ⅰ,FN1,α-SMA mRNA:Compared with the control group,the relative expression of the mRNAs in the mouse lung tissue in the model group in the mouse lung tissue is significantly increased(P<0.01);Compared with the model group,the relative expression of the mRNA of COL-Ⅰ,FN1,and α-SMA in the mouse lung tissue of the high dose group of Bufei Huoxue Capsule and PFD group mouse lung tissue is significantly down(P<0.01).The relatively mRNA expression level of COL-Ⅰ,FN1,α-SMA in the high dose group of the Bufei Huoxue Capsule and the pirfenidone group was similar,and the difference was not statistically significant.5.P-PI3K,p-Akt protein expression quantity:Compared with the control group,p-PI3K in the mouse lung tissue in the model group,the expression of p-Akt protein Compared with the p-PI3K in the high dose group of Bufei Huoxue Capsule and the PFD group mouse,the expression of p-Akt protein was significantly reduced(P<0.01).The expression of p-PI3K,p-Akt in the high dose group of the Bufei Huoxue Capsule and the pirfenidone group was similar,and the difference was not statistically significant.Conclusion:1.Professor Wang Yuguang classifies diffuse parenchymal lung disease as "pulmonary paralysis" and believes that the pathogenesis is mainly due to external toxicity,environmental toxicity or pharmacological toxicity that affects the lung,resulting in damage to the lung arteries,failure of the flow of Qi and blood,stagnation of the lung arteries,loss of circulation and descent,paralysis and obstruction,and the involvement of other organs over time,resulting in deficiency of the lung,spleen and kidney.The disease is always caused by Qi not taking in Blood,Qi not moving Blood,resulting in Blood leaving the meridians,Blood stagnation and stagnant Blood;or Lung Qi deficiency,Lung Qi deficiency,loss of Xuanjiang,loss of fluid distribution,fluid stagnation and phlegm.Phlegm and stagnation of blood,stagnation of blood and stagnation of heat are seen together,and the problem is caused by the internal visitors to the lung.The core pathogenesis can be summarized as Qi deficiency,blood stasis,phlegm-heat interjunction,and lung complex paralysis.The core pathogenesis can be summarized as Qi deficiency and Blood stasis,Phlegm-Heat interconnection,and lung ligament paralysis.Clinically,it has been found that drugs that benefit Qi and invigorate Blood are more effective in the early and remission stages of diffuse parenchymal lung disease.2.Bufei Huoxue Capsule has anti-fibrotic effect,its efficacy mechanism may be related to the inhibition of myofibroblast differentiation,obstruction of collagen synthesis and reduction of extracellular matrix deposition.Based on the immunohistochemical results,it is known that Bufei Huoxue Capsule has certain inhibitory effect on PI3K/Akt signaling pathway,so it is believed that it may treat pulmonary fibrosis by regulating PI3K/Akt signaling pathway.